Daito Pharmaceutical Co.,Ltd.
4577.T · JPX
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥50,643 | ¥46,895 | ¥45,101 | ¥43,464 |
| % Growth | 8% | 4% | 3.8% | – |
| Cost of Goods Sold | ¥42,005 | ¥37,056 | ¥34,770 | ¥32,005 |
| Gross Profit | ¥8,638 | ¥9,839 | ¥10,331 | ¥11,459 |
| % Margin | 17.1% | 21% | 22.9% | 26.4% |
| R&D Expenses | ¥0 | ¥2,349 | ¥1,865 | ¥1,749 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥6,017 | ¥3,431 | ¥3,078 | ¥2,990 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥165 | ¥180 | ¥166 |
| Operating Expenses | ¥6,017 | ¥5,945 | ¥5,123 | ¥4,905 |
| Operating Income | ¥2,621 | ¥3,894 | ¥5,207 | ¥6,553 |
| % Margin | 5.2% | 8.3% | 11.5% | 15.1% |
| Other Income/Exp. Net | ¥337 | ¥324 | -¥130 | ¥167 |
| Pre-Tax Income | ¥2,958 | ¥4,218 | ¥5,076 | ¥6,720 |
| Tax Expense | ¥1,192 | ¥1,040 | ¥1,549 | ¥2,092 |
| Net Income | ¥1,908 | ¥3,295 | ¥3,600 | ¥4,668 |
| % Margin | 3.8% | 7% | 8% | 10.7% |
| EPS | 62.72 | 105 | 113.82 | 152.45 |
| % Growth | -40.3% | -7.7% | -25.3% | – |
| EPS Diluted | 62.72 | 105 | 113.71 | 152.45 |
| Weighted Avg Shares Out | 30 | 16 | 16 | 15 |
| Weighted Avg Shares Out Dil | 30 | 16 | 16 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥1 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥123 | ¥41 | ¥12 | ¥9 |
| Depreciation & Amortization | ¥4,332 | ¥3,659 | ¥3,870 | ¥3,313 |
| EBITDA | ¥7,413 | ¥7,920 | ¥8,958 | ¥9,881 |
| % Margin | 14.6% | 16.9% | 19.9% | 22.7% |